The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00988117
Recruitment Status : Completed
First Posted : October 1, 2009
Results First Posted : February 26, 2014
Last Update Posted : February 26, 2014
Information provided by (Responsible Party):
Bruce Miller, University of California, San Francisco

Brief Summary:
This is an open-label study to investigate the effects of the rivastigmine patch on attention and behavior in Parkinson's disease when associated with memory and/or thinking problems. Rivastigmine (also sold under the name Exelon) is an FDA approved medication used for the treatment of mild to moderate Alzheimer's Disease (AD) and memory or thinking problems due to Parkinson's disease. Recently a rivastigmine patch was developed, which has shown similar effectiveness with fewer side effects and increased caregiver preference when compared to capsules. This is an open-label 12 week study where 15 subjects diagnosed with Parkinson's Disease who have mild to moderate memory and/or thinking complaints will be treated with the rivastigmine patch at UCSF. This study also analyzes the mechanism by which the rivastigmine patch works in people with Parkinson's disease and memory and/or thinking problems.

Condition or disease Intervention/treatment Phase
Parkinsons Disease With Dementia Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems Drug: Rivastigmine Patch 9.5 cm2 Phase 4

Detailed Description:

Participation in this study requires four visits: a screening visit to ensure eligibility, an initial/baseline visit where the medication is distributed at a dosage lower than the optimal recommended dosage, a four week follow-up visit where the dosage of the medication is increased to the optimal amount, and a final twelve week follow up visit.

  • In the screening visit the patient will undergo a neurological exam (including a review of their medical history and short physical exam), electrocardiogram ( a painless procedure that measures electrical activity of your heart), cognitive testing (such as memory and thinking tests), and a blood draw.
  • At the Baseline/Initial visit the patient will receive a brief physical exam, additional cognitive testing, and an MRI scan. Afterwards, the study drug will be distributed.
  • At the four week follow up visit the patient will be asked to do some abbreviated cognitive and neurological testing and the study drug will be re-distributed at the target dosage.
  • At the final twelve week visit the patient will receive additional cognitive and neurological testing, and an MRI scan.
  • Study compliance and adverse events will be reviewed every two weeks throughout the study, whether in person or over the phone.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)
Study Start Date : April 2010
Actual Primary Completion Date : April 2011
Actual Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Rivastigmine Patch 9.5 cm2 Drug: Rivastigmine Patch 9.5 cm2
Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.

Primary Outcome Measures :
  1. Resting State Functional Activity Change From Baseline to 12 Weeks [ Time Frame: Baseline and 12 weeks ]
    Fractional amplitude of low frequency fluctuations (fALFF) was used to measure brain activity. This metric is derived from task-free functional magnetic resonance imaging (fMRI) and represents the power of regional spontaneous and intrinsic brain activity at the local, voxel-wise level while the subject is at rest. More specifically, the amplitude of low-frequency fluctuations (ALFF) is the total power in the low-frequency range, and fALFF is calculated by dividing ALFF by the total power across all measurable frequencies. Whereas ALFF values increase near blood vessels and cerebrospinal fluid (CSF), likely due to pulsations in those areas, fALFF is less susceptible to artifactual signals. We measured change in these ratio scores post-treatment minus baseline and present in z-score units.

  2. Pre-post Change in Continuous Performance Test of Attention (Median Reaction Time) [ Time Frame: Baseline and 12 weeks ]
    On the Continuous Performance Test (CPT), subjects press the spacebar quickly when they see a target image (a white star; 150 trials), and withhold response when they see a non-target image (5 randomly sampled white shapes; 150 trials). The inter-stimulus interval is randomly sampled from 1.5s, 2.5s, or 4s. Performance is measured by the median reaction time (milliseconds) on accurate target trials.

Secondary Outcome Measures :
  1. Pre-post Change in Montreal Cognitive Assessment [ Time Frame: Baseline and 12 weeks ]
    The Montreal Cognitive Assessment (MoCA) was used as measure of global cognitive function. Total scores range from 0 (worst) to 30 (best).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must meet research criteria for Parkinson's Disease with Dementia (PDD)
  • Males and females, ages between 55 and 100
  • Able to undergo psychometric testing
  • Mini-Mental State Examination ≥ 21 and Clinical Dementia Rating < 2
  • Reliable informant with frequent contact with patient

Exclusion Criteria:

  • Non-English speaking, as cognitive tests will be in English
  • Evidence of other neurological or psychiatric disorders which preclude diagnosis of PDD (including, but not limited to, stroke, any psychotic disorder, severe bipolar or unipolar depression, seizure disorder, or head injury with loss of consciousness) within the past year
  • Concurrent treatment with any acetylcholinesterase inhibitors (including rivastigmine in pill or patch form), antipsychotic agents (excluding quetiapine in dosages of 150 mg and lower, abilify and geodon as these medications are commonly used in treatment of Parkinson's Disease (PD) psychosis and should not affect results of study), mood stabilizers (valproate or lithium) or benzodiazepines (other than temazepam or zolpidem)
  • Positive urine drug screen or suspected alcohol or substance abuse within last 1 year
  • Current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included
  • Systolic blood pressure over 180 or less than 90 mm Hg. Diastolic blood pressure not greater than 105 or less than 50 mm Hg
  • ECG is abnormal and judged to be clinically significant by the investigator
  • Use of investigational drugs or participation in investigational drug studies within 30 days of screening
  • Geriatric Depression Score score > 15/30
  • Hachinski score > 4

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00988117

United States, California
UCalifornia SF
San Francisco, California, United States, 94117
Sponsors and Collaborators
University of California, San Francisco
Principal Investigator: Bruce Miller, M.D. UCalifornia SF
Study Director: Joel Kramer, PsyD UCalifornia SF

Additional Information:
Publications of Results:
Responsible Party: Bruce Miller, Director of the Memory & Aging Center, University of California, San Francisco Identifier: NCT00988117     History of Changes
Other Study ID Numbers: CENA7 13D US45T
First Posted: October 1, 2009    Key Record Dates
Results First Posted: February 26, 2014
Last Update Posted: February 26, 2014
Last Verified: January 2014

Keywords provided by Bruce Miller, University of California, San Francisco:
Parkinson's Disease with Dementia
rivastigmine patch
open label
Parkinson's Disease
Parkinsons Disease
Exelon Patch

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents